U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H10N2O2
Molecular Weight 262.2628
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of INDIRUBIN

SMILES

O=C1NC2=C(C=CC=C2)\C1=C3\NC4=C(C=CC=C4)C3=O

InChI

InChIKey=CRDNMYFJWFXOCH-YPKPFQOOSA-N
InChI=1S/C16H10N2O2/c19-15-10-6-2-4-8-12(10)17-14(15)13-9-5-1-3-7-11(9)18-16(13)20/h1-8,17H,(H,18,20)/b14-13-

HIDE SMILES / InChI

Molecular Formula C16H10N2O2
Molecular Weight 262.2628
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Indirubin is derived from the Indigo Plant (Isatis Root, Isatis Leaf). It is used as part of a traditional Chinese herbal prescription called Dang Gui Long Hui Wan, to treat chronic myelogenous leukemia (CML). Indirubin inhibits DNA synthesis in several cell lines, in a cell-free assay and in vivo in rats with Walker-256 sarcoma. A weak binding of indirubin to DNA in vitro has been described. Indirubin inhibited all cyclin-dependent kinases (1,2,4,5) almost equally. Indirubin has been approved for clinical trials against chronic myelocytic and chronic granulocytic leukaemia. A few studies show that Indirubin is effective against psoriasis. Mild to severe nausea, vomiting, abdominal pain, diarrhea, headache, and edema are reported adverse events of Indirubin. Long-term oral ingestion has also occasionally been associated with hepatitis, pulmonary arterial hypertension and cardiac insufficiency.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
2.2 µM [IC50]
5.5 µM [IC50]
7.5 µM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown
Primary
Unknown

Doses

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

PubMed

Sample Use Guides

In Vivo Use Guide
Oral: 150–200 mg per day Topical: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily (Indirubin 10 or 50 or 100 or 200 ug/g of oinment)
Route of Administration: Other
In Vitro Use Guide
Indirubin exhibited activity against dermatophytes such as Epidermophyton floccosum (MIC=6.25 ug/ml); Trichophyton rubrum and Trichophyton tonsurans (MIC=25 ug/ml); Trichophyton mentagrophytes and Trichophyton simii (MIC=50 ug/ml). It was also active against non-dermatophytes (Aspergillus niger, Candida albicans and Cryptococcus sp.) within a MIC range of 0.75-25 ug/ml.
Substance Class Chemical
Record UNII
V86L8P74GI
Record Status Validated (UNII)
Record Version